- Global Pharma News & Resources

Press Releases - 2020-03-03

Date Title Company
03-Mar-2020 Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update Syndax Pharmaceuticals, Inc.
03-Mar-2020 DURECT Corporation Announces Fourth Quarter and Full Year 2019 Financial Results and Update of Programs DURECT Corporation
03-Mar-2020 Kindred Biosciences to Announce Fourth Quarter and Year-End 2019 Financial Results Kindred Biosciences, Inc.
03-Mar-2020 MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab (news with additional features) MorphoSys AG
03-Mar-2020 FDA Informs Patients, Providers and Manufacturers About Potential Cybersecurity Vulnerabilities in Certain Medical Devices with Bluetooth Low Energy U.S. Food and Drug Administration
03-Mar-2020 Eckert & Ziegler to Financially Back Clinical Development of Innovative Lymphoma Treatment Eckert & Ziegler Strahlen- und Medizintechnik AG
03-Mar-2020 Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs Chi-Med
03-Mar-2020 Autolus Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Progress Autolus Therapeutics plc
03-Mar-2020 Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Takeda Pharmaceutical Company Limited
03-Mar-2020 PolyProx Therapeutics raises an additional £1 million seed financing from new investor, LifeArc, to validate polyproxin® drug leads in oncology PolyProx Therapeutics
03-Mar-2020 GE Healthcare Life Sciences to manufacture RevoluGen’s Fire Monkey / Fire Flower product for enabling long-read DNA sequencing GE Healthcare Life Sciences
03-Mar-2020 Gilead Sciences entered into a definitive agreement to acquire Forty Seven for $95.50 per share in cash, or approximately $4.9 billion, further boosting the company's immuno-oncology presence. Gilead Sciences
03-Mar-2020 Rectal Cancer Therapeutics Pipeline Analysis and Developments Pharma Proff
03-Mar-2020 Celltrion Healthcare launch Remsima® SC in UK Celltrion Healthcare
03-Mar-2020 FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma Sanofi
03-Mar-2020 PureTech Announces First Participant Dosed in Clinical Trial of Wholly-Owned Lymphoedema Candidate LYT-100 PureTech Health
03-Mar-2020 Vifor Pharma Secures a Second Investment Grade Rating From Fitch Ratings Vifor Pharma Group
03-Mar-2020 Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses Transgene
03-Mar-2020 Phase 2b study on track to complete recruitment in mid-2020 Earlier grant funded programs progressing to plan Company well-funded through to mid-2021 Destiny Pharma plc
03-Mar-2020 Vifor Pharma secures a second investment grade rating from Fitch Ratings Vifor Pharma Group